Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis from Gastrointestinal cancer: a phase I study.
Phase 1
Recruiting
- Conditions
- Patients with advanced, irresectable peritoneal metastases (PM)originating from gastrointestinal (GI) cancer (colorectal, small bowel,appendix, stomach, pancreatic, cholangiocarcinoma)Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-509135-17-00
- Lead Sponsor
- niversitair Ziekenhuis Gent
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method